TY - JOUR AU - Kola, Job Baffin AU - Turarova, Botagoz AU - Csige, Dóra AU - Sipos, Ádám AU - Fodor-Varga, Luca Anna AU - Gergely, Bence AU - Refai, Farah Al AU - Uray, Iván AU - Docsa, Tibor AU - Uray (Davis), Karen L. TI - Stretch-Induced Down-Regulation of HCN2 Suppresses Contractile Activity JF - MOLECULES J2 - MOLECULES VL - 28 PY - 2023 IS - 11 SN - 1420-3049 DO - 10.3390/molecules28114359 UR - https://m2.mtmt.hu/api/publication/33897225 ID - 33897225 AB - Although hyperpolarization-activated and cyclic nucleotide-gated 2 channels (HCN2) are expressed in multiple cell types in the gut, the role of HCN2 in intestinal motility is poorly understood. HCN2 is down-regulated in intestinal smooth muscle in a rodent model of ileus. Thus, the purpose of this study was to determine the effects of HCN inhibition on intestinal motility. HCN inhibition with ZD7288 or zatebradine significantly suppressed both spontaneous and agonist-induced contractile activity in the small intestine in a dose-dependent and tetrodotoxin-independent manner. HCN inhibition significantly suppressed intestinal tone but not contractile amplitude. The calcium sensitivity of contractile activity was significantly suppressed by HCN inhibition. Inflammatory mediators did not affect the suppression of intestinal contractile activity by HCN inhibition but increased stretch of the intestinal tissue partially attenuated the effects of HCN inhibition on agonist-induced intestinal contractile activity. HCN2 protein and mRNA levels in intestinal smooth muscle tissue were significantly down-regulated by increased mechanical stretch compared to unstretched tissue. Increased cyclical stretch down-regulated HCN2 protein and mRNA levels in primary human intestinal smooth muscle cells and macrophages. Overall, our results suggest that decreased HCN2 expression induced by mechanical signals, such as intestinal wall distension or edema development, may contribute to the development of ileus. LA - English DB - MTMT ER - TY - JOUR AU - Furka, Andrea AU - Nagy, Zsofia AU - Szabó, Imre AU - Fekete, Gábor AU - Kelemen, Ágnes AU - Bolobás, Gábor AU - Sebők, Gábriel AU - Molnár, Tünde AU - Árvai, János AU - Tornyi, Ilona AU - Kostyál, László AU - Révész, János AU - Hauser, Péter TI - Full Body Surface Coverage with Water-Equivalent Bolus as Novel Technique for Total Body Irradiation before Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia JF - CHILDREN (BASEL) J2 - CHILDREN-BASEL VL - 9 PY - 2022 IS - 11 SN - 2227-9067 DO - 10.3390/children9111740 UR - https://m2.mtmt.hu/api/publication/33238498 ID - 33238498 AB - Background: Total body irradiation (TBI) 2 × 2 Gy for 3 consecutive days followed by chemotherapy for conditioning pediatric patients with acute lymphoid leukemia (ALL) before bone marrow transplantation is superior to chemo-conditioning alone. The globally used anterior-posterior/posterior-anterior (AP/PA) technique is the most referable method, but volumetric modulated arc therapy (VMAT) with modern linear accelerators is more precise in terms of ensuring better dose distribution, especially for skin, and higher protection of organs at risk, resulting in less side effects. Method: For TBI, a modern VMAT technique was used. Whole-body immobilization in the supine position was performed using a vacuum mattress with a full body coverage, with a water-equivalent bolus of 1 cm thickness. The design goal was to achieve dose inhomogeneity of less than ±10%. Results: From 2020 to 2022, we performed TBI for five pediatric patients with ALL, with full body bolus and VMAT, who later received hematopoietic stem cell transplantation. No acute complications related to TBI were observed during the treatment period with a median follow-up of 1.27 (0.43–2.11) years. Conclusion: Using full body water-equivalent bolus with VMAT for TBI provides a safe method for children with a better organ sparing in the short term follow-up. LA - English DB - MTMT ER - TY - JOUR AU - Rini, Brian I AU - Plimack, Elizabeth R AU - Stus, Viktor AU - Gafanov, Rustem AU - Hawkins, Robert AU - Nosov, Dmitry AU - Pouliot, Frédéric AU - Alekseev, Boris AU - Soulières, Denis AU - Melichar, Bohuslav AU - Vynnychenko, Ihor AU - Kryzhanivska, Anna AU - Bondarenko, Igor AU - Azevedo, Sergio J AU - Borchiellini, Delphine AU - Szczylik, Cezary AU - Markus, Maurice AU - McDermott, Raymond S AU - Bedke, Jens AU - Tartas, Sophie AU - Chang, Yen-Hwa AU - Tamada, Satoshi AU - Shou, Qiong AU - Perini, Rodolfo F AU - Chen, Mei AU - Atkins, Michael B AU - Powles, Thomas ED - Bastos, Diogo / Collaborator ED - de Azevedo, Sergio Jobim / Collaborator ED - Marinho, Gisele / Collaborator ED - Murad, Andre Marcio / Collaborator ED - Schutz, Fabio / Collaborator ED - Zucca, Luis Eduardo / Collaborator ED - Zylberberg, Ricardo / Collaborator ED - Hotte, Sebastien / Collaborator ED - Pouliot, Frederic / Collaborator ED - Soulières, Denis / Collaborator ED - Wood, Lori / Collaborator ED - Finek, Jindrich / Collaborator ED - Holeckova, Petra / Collaborator ED - Katolicka, Jana / Collaborator ED - Kindlova, Eva / Collaborator ED - Melichar, Bohuslav / Collaborator ED - Prausova, Jana / Collaborator ED - Abadie-Lacourtoisie, Sophie / Collaborator ED - Bennamoun, Mostefa / Collaborator ED - Chevreau, Christine / Collaborator ED - Deville, Jean / Collaborator ED - El Kouri, Claude / Collaborator ED - Borchiellini, Delphine / Collaborator ED - Ferrero, Jean-Marc / Collaborator ED - Geoffrois, Lionnel / Collaborator ED - Gross-Goupil, Marine / Collaborator ED - Le Brun Ly, Valerie / Collaborator ED - Laplante, Marc / Collaborator ED - Linassier, Claude / Collaborator ED - Oudard, Stephane / Collaborator ED - Tartas, Sophie / Collaborator ED - Topart, Delphine / Collaborator ED - Tourani, Jean-Marc / Collaborator ED - Bedke, Jens / Collaborator ED - Boegemann, Martin / Collaborator ED - Lorch, Anja / Collaborator ED - Merseburger, Axel / Collaborator ED - Reichardt, Peter / Collaborator ED - Retz, Margitta / Collaborator ED - Wirth, Manfred / Collaborator ED - Wuelfing, Christian / Collaborator ED - Árkosy, Péter / Collaborator ED - Horváth, Zsolt / Collaborator ED - Bodoky, György / Collaborator ED - Csejtei, Andras / Collaborator ED - Csoszi, Tibor / Collaborator ED - Géczi, Lajos / Collaborator ED - Révész, János / Collaborator ED - Ruzsa, Agnes / Collaborator ED - McCaffrey, John / Collaborator ED - McDermott, Raymond S / Collaborator ED - Anai, Satoshi / Collaborator ED - Eto, Masatoshi / Collaborator ED - Inoue, Takaaki / Collaborator ED - Kato, Haruaki / Collaborator ED - Kimura, Go / Collaborator ED - Kobayashi, Hiroaki / Collaborator ED - Kojima, Takahiro / Collaborator ED - Masumori, Naoya / Collaborator ED - Matsubara, Akio / Collaborator ED - Matsubara, Nobuaki / Collaborator ED - Matsumoto, Hiroaki / Collaborator ED - Mizuno, Ryuichi / Collaborator ED - Nakaigawa, Noboru / Collaborator ED - Nishimura, Kazuo / Collaborator ED - Osawa, Takahiro / Collaborator ED - Miyajima, Naoto / Collaborator ED - Oyama, Masafumi / Collaborator ED - Sugimura, Yoshiki / Collaborator ED - Takahashi, Masayuki / Collaborator ED - Takano, Toshimi / Collaborator ED - Tamada, Satoshi / Collaborator ED - Tomita, Yoshihiko / Collaborator ED - Tsujihata, Masao / Collaborator ED - Tsunemori, Hiroyuki / Collaborator ED - Uemura, Hirotsugu / Collaborator ED - Yamaguchi, Akito / Collaborator ED - Langiewicz, Przemyslaw / Collaborator ED - Szczylik, Cezary / Collaborator ED - Tomczak, Piotr / Collaborator ED - Wiechno, Pawel / Collaborator ED - Wojcik-Tomaszewska, Joanna / Collaborator ED - Pikiel, Joanna / Collaborator ED - Ziobro, Marek / Collaborator ED - Alekseev, Boris / Collaborator ED - Gafanov, Rustem / Collaborator ED - Karlov, Petr / Collaborator ED - Matveev, Vsevolod / Collaborator ED - Nosov, Dmitry / Collaborator ED - Shkolnik, Michail / Collaborator ED - Bae, Woo Kyun / Collaborator ED - Lee, Hyo Jin / Collaborator ED - Castellano Gauna, Daniel / Collaborator ED - Juan Fita, Maria / Collaborator ED - Rodriguez-Vida, Alejo / Collaborator ED - Suarez, Cristina / Collaborator ED - Chang, Chao-Hsiang / Collaborator ED - Chang, Wen-Cheng / Collaborator ED - Chuang, Cheng Keng / Collaborator ED - Chung, Hsiao-Jen / Collaborator ED - Chang, Yen-Hwa / Collaborator ED - Bondarenko, Igor / Collaborator ED - Kryzhanivska, Anna / Collaborator ED - Sakalo, Valerii / Collaborator ED - Shparyk, Yaroslav / Collaborator ED - Stus, Viktor / Collaborator ED - Vynnychenko, Ihor / Collaborator ED - Hawkins, Robert / Collaborator ED - Larkin, James / Collaborator ED - Powles, Thomas / Collaborator ED - Wheater, Matthew / Collaborator ED - Amin, Asim / Collaborator ED - Appleman, Leonard / Collaborator ED - Aragon-Ching, Jeanny / Collaborator ED - Berg, Alan / Collaborator ED - Dunder, Steven / Collaborator ED - Cho, Daniel / Collaborator ED - Doshi, Gurjyot / Collaborator ED - Fruehauf, John / Collaborator ED - Fung, Chunkit / Collaborator ED - George, Saby / Collaborator ED - Graham, Robert / Collaborator ED - Hammers, Hans / Collaborator ED - Brugarolas, James / Collaborator ED - Kam, Audrey / Collaborator ED - Pfanzelter, Nicklas / Collaborator ED - Kendall, Stephan DiSean / Collaborator ED - Markus, Maurice / Collaborator ED - Cohn, Allen / Collaborator ED - Matrana, Marc / Collaborator ED - Nair, Suresh / Collaborator ED - Oyola, Raul / Collaborator ED - Plimack, Elizabeth / Collaborator ED - Rini, Brian / Collaborator ED - Ryan, Christopher / Collaborator ED - Schnadig, Ian / Collaborator ED - Somer, Bradley / Collaborator ED - Sosman, Jeffrey / Collaborator ED - Carneiro, Benedito / Collaborator ED - Sumey, Christoper / Collaborator ED - Sundararajan, Srinath / Collaborator ED - Singh, Parminder / Collaborator ED - Bukowski, Ronald / Collaborator ED - Dutcher, Janice P / Collaborator ED - Kim, KyungMann / Collaborator ED - Kuzel, Timothy M / Collaborator TI - Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 380 PY - 2019 IS - 12 SP - 1116 EP - 1127 PG - 12 SN - 0028-4793 DO - 10.1056/NEJMoa1816714 UR - https://m2.mtmt.hu/api/publication/31239122 ID - 31239122 N1 - Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't AB - The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis.After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group.Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.). LA - English DB - MTMT ER - TY - GEN AU - Barabás, Loránd AU - Gráf, László AU - Garam, Nóra AU - Kocsis, Judit AU - Prohászka, Zoltán AU - István, Gábor AU - Herszényi, László TI - Az MMP-9, TIMP-1 és TIMP-2 viselkedése colorectalis carcinomában, Coloproctológiai Szekció és Sebészeti Endoszkópos Szekciójának 2019. évi közös Kongresszusa, Siófok. PY - 2019 UR - https://m2.mtmt.hu/api/publication/31121921 ID - 31121921 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Forster, Martin D AU - Dillon, Magnus T AU - Kocsis, Judit AU - Remenár, Éva AU - Pajkos, Gabor AU - Rolland, Frederic AU - Greenberg, Jonathan AU - Harrington, Kevin J TI - Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck. A randomised phase II study. TS - A randomised phase II study. JF - EUROPEAN JOURNAL OF CANCER J2 - EUR J CANCER VL - 123 PY - 2019 SP - 36 EP - 47 PG - 12 SN - 0959-8049 DO - 10.1016/j.ejca.2019.08.017 UR - https://m2.mtmt.hu/api/publication/30915378 ID - 30915378 LA - English DB - MTMT ER - TY - JOUR AU - Pakurár, Miklós AU - Haddad, Hossam AU - Nagy, János AU - Popp, József AU - Oláh, Judit TI - The Impact of Supply Chain Integration and Internal Control on Financial Performance in the Jordanian Banking Sector JF - SUSTAINABILITY J2 - SUSTAINABILITY-BASEL VL - 11 PY - 2019 IS - 5 PG - 20 SN - 2071-1050 DO - 10.3390/su11051248 UR - https://m2.mtmt.hu/api/publication/30482090 ID - 30482090 LA - English DB - MTMT ER - TY - JOUR AU - Pakurár, Miklós AU - Haddad, Hossam AU - Nagy, János AU - Popp, József AU - Oláh, Judit TI - The Service Quality Dimensions that Affect Customer Satisfaction in the Jordanian Banking Sector JF - SUSTAINABILITY J2 - SUSTAINABILITY-BASEL VL - 11 PY - 2019 IS - 4 PG - 24 SN - 2071-1050 DO - 10.3390/su11041113 UR - https://m2.mtmt.hu/api/publication/30450395 ID - 30450395 LA - English DB - MTMT ER - TY - JOUR AU - Cohen, Ezra E W AU - Soulières, Denis AU - Le Tourneau, Christophe AU - Dinis, José AU - Licitra, Lisa AU - Ahn, Myung-Ju AU - Soria, Ainara AU - Machiels, Jean-Pascal AU - Mach, Nicolas AU - Mehra, Ranee AU - Burtness, Barbara AU - Zhang, Pingye AU - Cheng, Jonathan AU - Swaby, Ramona F AU - Harrington, Kevin J ED - Acosta-Rivera, Mirelis / Collaborator ED - Adkins, Douglas R / Collaborator ED - Aghmesheh, Morteza / Collaborator ED - Ahn, Myung-Ju / Collaborator ED - Airoldi, Mario / Collaborator ED - Aleknavicius, Eduardas / Collaborator ED - Al-Farhat, Yousuf / Collaborator ED - Algazi, Alain P / Collaborator ED - Almokadem, Salah / Collaborator ED - Alyasova, Anna / Collaborator ED - Bauman, Jessica R / Collaborator ED - Benasso, Marco / Collaborator ED - Berrocal, Alfonso / Collaborator ED - Bray, Victoria / Collaborator ED - Burtness, Barbara Ann / Collaborator ED - Caponigro, Francesco / Collaborator ED - Castro, Ana / Collaborator ED - Cescon, Terrence P / Collaborator ED - Chan, Kelvin / Collaborator ED - Chaudhry, Arvind / Collaborator ED - Chauffert, Bruno / Collaborator ED - Cohen, Ezra / Collaborator ED - Csoszi, Tibor / Collaborator ED - De Boer, J P / Collaborator ED - Delord, Jean-Pierre / Collaborator ED - Dietz, Andreas / Collaborator ED - Dinis, Jose / Collaborator ED - Dupuis, Charlotte / Collaborator ED - Digue, Laurence / Collaborator ED - Erfan, Jozsef / Collaborator ED - Escobar Alvarez, Yolanda / Collaborator ED - Evans, Mererid / Collaborator ED - Fidler, Mary Jo / Collaborator ED - Forster, Martin David / Collaborator ED - Friesland, Signe / Collaborator ED - Ganti, Apar K / Collaborator ED - Geoffrois, Lionnel / Collaborator ED - Grant, Cliona / Collaborator ED - Gruenwald, Viktor / Collaborator ED - Harrington, Kevin / Collaborator ED - Hoffmann, Thomas / Collaborator ED - Horvai, Geza / Collaborator ED - Inciura, Arturas / Collaborator ED - Jang, Raymond / Collaborator ED - Jankowska, Petra / Collaborator ED - Jimeno, Antonio / Collaborator ED - Joseph, Mano / Collaborator ED - Juarez Ramiro, Alejandro / Collaborator ED - Karaszewska, Boguslawa / Collaborator ED - Kawecki, Andrzej / Collaborator ED - Keilholz, Ulrich / Collaborator ED - Keller, Ulrich / Collaborator ED - Kim, Sung-Bae / Collaborator ED - Kocsis, Judit / Collaborator ED - Kotecki, Nuria / Collaborator ED - Kozloff, Mark F / Collaborator ED - Lambea, Julio / Collaborator ED - Landherr, Laszlo / Collaborator ED - Lantsukhay, Yuri / Collaborator ED - Lazarev, Sergey Alexandrovich / Collaborator ED - Lee, Lip Way / Collaborator ED - Le Tourneau, Christophe / Collaborator ED - Licitra, Lisa / Collaborator ED - Lifirenko, Igor Dmitrievich / Collaborator ED - Mach, Nicolas / Collaborator ED - Martincic, Danko / Collaborator ED - Matorin, Oleg Vladmirovhich / Collaborator ED - McGrath, Margaret / Collaborator ED - Machiels, Jean-Pascal / Collaborator ED - Mehra, Ranee / Collaborator ED - Misiukiewicz, Krzysztof / Collaborator ED - Morris, John C / Collaborator ED - Mufazalov, Fagim Fanisovich / Collaborator ED - Niu, Jiaxin / Collaborator ED - Pamoorthy Srinivasan, Devraj / Collaborator ED - Perez Segura, Pedro / Collaborator ED - Rauch, Daniel / Collaborator ED - Ribeiro, Maria Leonor / Collaborator ED - Rodriguez, Cristina / Collaborator ED - Rolland, Frederic / Collaborator ED - Russo, Antonio / Collaborator ED - Ruzsa, Agnes / Collaborator ED - Sanches, Frederico / Collaborator ED - Shin, Sang-Won / Collaborator ED - Shtiveland, Mikhail / Collaborator ED - Soulieres, Denis / Collaborator ED - Soria, Ainara / Collaborator ED - Specenier, Pol / Collaborator ED - Szekanecz, Eva / Collaborator ED - Szota, Judit / Collaborator ED - van Herpen, Carla M L / Collaborator ED - Velez-Cortes, Hector A / Collaborator ED - Walsh, William V / Collaborator ED - Wilop, Stefan / Collaborator ED - Winterhalder, Ralph / Collaborator ED - Wojtukiewicz, Marek / Collaborator ED - Wong, Deborah / Collaborator ED - Zandberg, Dan / Collaborator TI - Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study JF - LANCET J2 - LANCET VL - 393 PY - 2019 IS - 10167 SP - 156 EP - 167 PG - 12 SN - 0140-6736 DO - 10.1016/S0140-6736(18)31999-8 UR - https://m2.mtmt.hu/api/publication/30391276 ID - 30391276 AB - There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma.We did a randomised, open-label, phase 3 study at 97 medical centres in 20 countries. Patients with head-and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred or progressed within 3-6 months of previous multimodal therapy containing platinum for locally advanced disease, were randomly assigned (1:1) in blocks of four per stratum with an interactive voice-response and integrated web-response system to receive pembrolizumab 200 mg every 3 weeks intravenously or investigator's choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously (standard-of-care group). The primary endpoint was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT02252042, and is no longer enrolling patients.Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia).The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease.Merck Sharp & Dohme, a subsidiary of Merck & Co. LA - English DB - MTMT ER - TY - JOUR AU - Maráz, Anikó AU - Csejtei, A AU - Kocsis, Judit AU - Szűcs, Miklós AU - Kahán, Zsuzsanna AU - Bodoky, György AU - Dank, Magdolna AU - Mangel, László Csaba AU - Révész, János AU - Varga, Zoltán AU - Géczi, Lajos TI - Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 25 PY - 2019 IS - 1 SP - 149 EP - 156 PG - 8 SN - 1219-4956 DO - 10.1007/s12253-017-0317-0 UR - https://m2.mtmt.hu/api/publication/3275013 ID - 3275013 LA - English DB - MTMT ER - TY - JOUR AU - Lim, Ho Yeong AU - Merle, Philippe AU - Weiss, Karl Heinz AU - Yau, Thomas AU - Ross, Paul AU - Mazzaferro, Vincenzo AU - Blanc, Jean-Frederic AU - Ma, Yuk Ting AU - Yen, Chia Jui AU - Kocsis, Judit AU - Choo, Su Pin AU - Sukeepaisarnjaroen, Wattana AU - Gerolami, Rene AU - Dufour, Jean-Francois AU - Gane, Edward J. AU - Ryoo, Baek-Yeol AU - Peck-Radosavljevic, Markus AU - Thong, Dao AU - Yeo, Winnie AU - Lamlertthon, Wisut AU - Thongsawat, Satawat AU - Teufel, Michael AU - Roth, Katrin AU - Reis, Diego AU - Childs, Barrett H. AU - Krissel, Heiko AU - Llovet, Josep M. TI - Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma JF - CLINICAL CANCER RESEARCH J2 - CLIN CANCER RES VL - 24 PY - 2018 IS - 19 SP - 4650 EP - 4661 PG - 12 SN - 1078-0432 DO - 10.1158/1078-0432.CCR-17-3588 UR - https://m2.mtmt.hu/api/publication/31337984 ID - 31337984 LA - English DB - MTMT ER -